Log In
Print
BCIQ
Print
Print this Print this
 

Targin, oxycodone/naloxone (Targiniq ER)

  Manage Alerts
Collapse Summary General Information
Company Mundipharma International Ltd.
DescriptionAbuse-deterrent, extended-release/long-acting combination of oxycodone and naloxone
Molecular Target Kappa opioid receptor (OPRK1) (KOR) ; Mu opioid receptor (OPRM1) (MOR)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationPain
Indication DetailsTreat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treat severe pain that can only be adequately managed with opioid analgesics
Regulatory Designation

U.S. - Undisclosed Review (Treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate)

Partner

Purdue Pharma L.P.; Shionogi & Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today